Alterations in the global proteome and phosphoproteome in third-generation EGFR TKI resistance reveal drug targets to circumvent resistance

Lung cancer is the leading cause of cancer mortality worldwide. The treatment of lung cancer patients harboring mutant EGFR with orally administered EGFR tyrosine kinase inhibitors (TKIs) has been a paradigm shift. Osimertinib and rociletinib are third-generation irreversible EGFR TKIs targeting the...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Res
Prif Awduron: Zhang, Xu, Maity, Tapan K., Ross, Karen E., Qi, Yue, Cultraro, Constance M., Bahta, Meriam, Pitts, Stephanie, Keswani, Meghana, Gao, Shaojian, Nguyen, Khoa Dang P., Cowart, Julie, Kirkali, Fatos, Wu, Cathy, Guha, Udayan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8182571/
https://ncbi.nlm.nih.gov/pubmed/33727228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2435
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg